Edesa Biotech is trading at $2.70, up 5.06% after hours, with no confirmed catalyst identified. - The regular-session close was $2.57 on October 30; no confirmed company announcement dated that day explained the rise. - An October 29 report described the EB05 COVID-19 trial record as terminated, based on an October 26 update; it does not clearly explain the move. - Broader markets were sharply lower, but the evidence does not establish a market-driven reason.